INKT
MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. (INKT) has 6 SEC Form 4 filings (12 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jun 5, 2026.
- Industry:Biotechnology
- CEO:Jennifer S. Buell
- Employees:15
- HQ:New York City, NY, US
- IPO:2021-10-15
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$19K
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$52.8M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Ryan BarbaraFirst filing | Director | Sale | 1,500 | $19K | Jun 5 | SEC ↗ |
Related companies
MiNK Therapeutics, Inc. is in the Healthcare sector.